Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25823793 | 0.81 | TNKS (0.36) | LMNAMAPTMEN1PABPC1KMT2A | |
| SCHEMBL24312097 | 0.75 | ADORA3 (0.47) | LMNAMAPT | |
| SCHEMBL22017504 | 0.75 | GRM4 (0.40) | LMNAMAPTAPAF1CASP6 | |
| SCHEMBL22017501 | 0.73 | POLB (0.33) | APAF1CASP6 | |
| SCHEMBL22017505 | 0.72 | ADORA3 (0.50) | — | |
| SCHEMBL22017499 | 0.69 | LMNA (0.39) | LMNAMAPTAPAF1CASP6 | |
| SCHEMBL16657358 | 0.69 | DAO (0.47) | — | |
| SCHEMBL24312321 | 0.69 | HPD (0.33) | MAPT | |
| SCHEMBL22017503 | 0.69 | FEN1 (0.60) | LMNAMAPT | |
| SCHEMBL21676739 | 0.68 | ALOX5 (0.39) | LMNAAPAF1CASP6MEN1PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | LMNA 2991/4885MAPT 2929/4885APAF1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.